9results about "Lipocortins" patented technology

A drug for treating osteoporosis. Provided is the use of annexin A5 in the preparation of a composition or preparation having one or more uses selected from the group consisting of: (i) preventing and / or treating osteoporosis; (ii) inhibiting osteoclast activity; and (iii) reducing bone loss. The annexin A5 can prevent and / or treat osteoporosis by means of inhibiting osteoclast activity and preventing bone loss.

The present disclosure relates to polypeptides and polypeptide analogs derived from Annexin A1, and compositions comprising said polypeptides or polypeptide analogs for treating inflammatory and ischemic conditions.

The present invention provides synthetic polypeptides comprising an annexin V protein, or a functional portion or fragment or variant thereof, conjugated to a tumor antigen, or a functional portion or fragment or variant thereof. The invention further provides methods for making said synthetic polypeptides and their use in the treatment of proliferative diseases such as cancer and tumors originating therefrom.

Combinations of an apyrase and an annexin, including fusion proteins thereof, are synergistic antithrombotics that do not induce unwanted bleeding.

The combination of apyrase and annexin, including the fusion protein, is a synergistic antithrombotic agent that does not induce unwanted bleeding.

Disclosed are methods for selecting or identifying fusion-competent gametes. The methods can include providing a sample including gametes obtained from a subject; and contacting the sample with a reagent capable of binding Myomerger expressed on the surface of the gametes. The methods can also include isolating gametes bound by the reagent capable of binding Myomerger from gametes not bound by the reagent capable of binding Myomerger. Also disclosed are methods for contraception that include administering a reagent capable of binding Myomerger expressed on the surface of gametes to a subject. Also disclosed are compositions that include a reagent capable of binding Myomerger and a reagent capable of binding phosphatidylserine, as are kits that include the disclosed compositions.

The targeted delivery of growth factors, vasoactive peptides and other representative anabolic peptide drugs from different signaling cascades to bone fracture for accelerated healing is disclosed herein.

The present invention relates to a novel method, use, and composition of a molecule consisting of monomeric annexin A5 protein for the prevention or treatment of macular edema and one or more diseases, disorders, or conditions associated with and / or caused by macular edema. In a preferred embodiment, annexin A5 is administered systemically, for example, by intravenous administration.

The present disclosure relates to polypeptides and polypeptide analogues derived from Annexin A1 as well as compositions comprising said polypeptides or polypeptide analogues for treatment of inflammatory and ischemic conditions.